Obesity is one of the most expensive chronic diseases in America, contributing to diabetes, heart disease, stroke, arthritis, sleep apnea, and dozens of other medical conditions that collectively cost the healthcare system hundreds of billions of dollars each year. Yet for years, Medicare beneficiaries seeking treatment with highly effective GLP-1 medications have found themselves excluded from coverage simply because the drugs were prescribed for weight loss.
The Centers for Medicare & Medicaid Services has launched the Medicare GLP-1 Bridge Program, allowing eligible Medicare beneficiaries to obtain GLP-1 medications for obesity at a substantially reduced monthly cost through the end of 2027. For many patients, this represents an important step toward expanding access to treatments that have consistently demonstrated meaningful weight loss and improvements in overall health.
The program deserves credit for recognizing obesity as a chronic disease that warrants medical treatment rather than simply a lifestyle issue. But while the announcement has generated considerable excitement, the program raises several important questions that remain unanswered.
The first challenge is one that physicians and patients know all too well: prior authorization.
Reducing the cost of a medication does not necessarily mean patients will receive it quickly. Before many beneficiaries can begin treatment, physicians must document eligibility, submit clinical information, and wait for approval. If the request is denied, the appeals process can add weeks or even months before treatment begins.
READ: Sreedhar Potarazu | Guardrails, not a ‘License Raj’: Getting AI regulation right (June 29, 2026)
Prior authorization was originally designed to ensure appropriate use of expensive medications. In practice, however, it has evolved into one of the largest administrative burdens in healthcare. Physicians spend countless hours completing paperwork instead of caring for patients, while patients often experience delays that discourage them from pursuing treatment altogether.
For obesity, timing matters. Many patients finally seek treatment after years of struggling with their weight and associated health conditions. Delays caused by administrative hurdles can erode motivation and postpone improvements in health that could reduce future medical costs.
The second concern is the temporary nature of the program.
The Bridge Program is scheduled to end in December 2027. While demonstration programs are valuable for evaluating new policy approaches, obesity is not a temporary condition. Most patients require long-term treatment to maintain meaningful weight loss. Numerous studies have shown that discontinuing GLP-1 therapy often results in significant weight regain, reversing many of the health benefits achieved during treatment.
READ: Sreedhar Potarazu | The White Rabbit Effect: How AI is changing our relationship with time (June 25, 2026)
This creates uncertainty for both patients and physicians.
Should a patient begin therapy today if there is no clear understanding of what coverage will look like after 2027? Will Medicare continue the program? Will beneficiaries suddenly face thousands of dollars in annual out-of-pocket costs? These questions are difficult to answer because no long-term coverage strategy has yet been established.
Healthcare works best when patients and physicians can make decisions based on predictable treatment plans. Temporary coverage may encourage patients to start therapy, but uncertainty about future access may also discourage long-term adherence or lead some patients to postpone treatment altogether.
Cost is another consideration.
GLP-1 medications have the potential to reduce future healthcare spending by lowering rates of diabetes, cardiovascular disease, and obesity-related complications. However, they also represent one of the most expensive classes of medications currently available. Policymakers will need to balance the immediate cost of expanding coverage against the long-term savings generated by preventing chronic disease.
The answer should not simply be whether Medicare can afford these medications today, but whether the healthcare system can afford to continue treating the downstream complications of obesity without them.
Like every medication, GLP-1 therapies also require careful medical supervision.
Most patients tolerate these medications well, and the benefits often outweigh the risks when prescribed appropriately. Nevertheless, physicians must monitor for gastrointestinal side effects, dehydration, gallbladder disease, pancreatitis, nutritional issues related to rapid weight loss, and potential medication interactions.
READ: Sreedhar Potarazu | What AI can teach us about fatherhood (June 21, 2026)
As an ophthalmologist, I am particularly interested in the emerging reports describing a possible association between GLP-1 medications and nonarteritic anterior ischemic optic neuropathy (NAION), a rare condition that can result in sudden vision loss. While current evidence does not establish that GLP-1 medications directly cause this condition, the reports highlight the importance of continued research and careful monitoring, particularly in patients with vascular risk factors who may already be predisposed to optic nerve disease.
Patients should not interpret these rare reports as a reason to avoid treatment. Rather, they should understand that every medical therapy involves balancing benefits and risks through informed discussions with their physicians. Appropriate monitoring remains an essential part of safe care.
The Medicare GLP-1 Bridge Program represents meaningful progress. It acknowledges that obesity deserves evidence-based medical treatment and begins to address longstanding inequities in access for older Americans. But it should be viewed as the beginning of a larger conversation rather than the final answer.
A successful obesity strategy requires more than temporary coverage. It requires reducing unnecessary administrative barriers such as prior authorization, providing patients with confidence that treatment will remain available when clinically appropriate, investing in long-term safety monitoring, and creating policies that recognize obesity as the chronic disease that it is.
The bridge has been built. Now policymakers must decide whether they intend to complete the road.